---
document_datetime: 2023-09-21 17:09:09
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/infanrix-hexa-epar-procedural-steps-taken-authorisation_en.pdf
document_name: infanrix-hexa-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.52684
conversion_datetime: 2025-12-20 18:03:19.668018
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  SmithKline  Beecham  Biologicals  S.A.,  Belgium,  submitted  on  1  July  1999  to  the European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  a marketing  authorisation  in  accordance  with  the  Centralised  Procedure  for  the  medicinal  product Infanrix hexa (combined Diphtheria, Tetanus, acellular Pertussis, recombinant Hepatitis B, inactivated Poliovirus  and  Haemophilus  influenzae  type  b  vaccine)  falling  within  the  scope  of  Part  A  of  the Annex to Council Regulation No (EC) 2309/93.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

## Licensing status:

The product was not licensed in any country inside or outside the EU at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 30 July 1999.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on  11 October 1999).
- The Co-Rapporteur's first assessment report was circulated to all members of the CPMP on 6 October 1999 In its meeting on 9-10 November 1999, the Biotechnology Working Party (BWP) discussed the draft list of questions on Part II of the dossier and endorsed the (Co)-Rapporteurs' recommendation to the CPMP. A BWP report was prepared for adoption at the CPMP meeting on 16-18 November 1999.
- During  its  meeting  on  16-18  November  1999,  the  CPMP  agreed  on  the  consolidated  list  of questions to be sent to the applicant on 18 November 1999.
- The applicant submitted the responses to the consolidated list of questions on 23 December 1999.
- The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the applicant's responses to the consolidated list of questions to  all  CPMP  members  on 22 February 2000.
- During its meeting on 7-8 March 2000, the Biotechnology Working Party (BWP) discussed the draft  list  of  outstanding  issues  on  Part  II  of  the  dossier  and  endorsed  the  (Co)-Rapporteur's recommendation to the CPMP. A BWP report was prepared for adoption at the CPMP meeting on 14-16 March 2000.
- During its meeting on 14-16 March 2000, the CPMP agreed on a list of outstanding issues to be addressed by the company in writing (quality and safety issues) and during an oral explanation (safety issues) held on 24 May 2000.
- The applicant submitted the written responses to the outstanding issues on 3 May 2000.
- The  Rapporteur  circulated  a  further  assessment  report,  taking  into  account  the  company's

Dr. Daniel Brasseur

Co-Rapporteur:

Dr. Manfred Haase

<div style=\"page-break-after: always\"></div>

responses on the outstanding quality and safety issues, to all CPMP members on 12 May 2000.

- An ad hoc expert group meeting on clinical issues was held on 22 May 2000 and a report from this meeting was circulated to all CPMP members on 23 May 2000.
- The applicant submitted updated information relating to Part II.V of the dossier to all CPMP Members on 15 June 2000.
- The Rapporteur's assessment report on the supplementary information relating to Part II.V was circulated on 15 June 2000.
- During its meeting on 20-21 June 2000, the Biotechnology Working Party (BWP) discussed the Rapporteur's assessment report  on the supplementary information relating to  Part II.V  of the dossier and endorsed a recommendation to the CPMP. A BWP report was prepared for adoption at the CPMP meeting on 27-29 June 2000.
- During the meeting on 27-29 June 2000, the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  for  Infanrix  hexa  on  29  June  2000.  The  applicant  agreed  to  submit additional information regarding quality/clinical/safety data within the defined timeframe.